British regulators have received extra trial data from AstraZeneca that supports their view that the Covid-19 vaccine developed with Oxford University is effective in the elderly, a vaccines official said.
Britain has been rolling out the shot among all age groups after the Medicines and Healthcare products Regulatory Agency (MHRA) was the first regulator to approve it in December.
A number of European countries, including Ireland, have said more data is needed before it is given to those over 65. "Since (initial approval) we've seen more data coming through from AstraZeneca as more people are completing the trial, which highlights again that efficacy in the elderly is seen, and there's no evidence of lack of efficacy," Munir Pirmohamed,